How organoids can improve personalized treatment in patients with gastro-esophageal tumors

IF 4 3区医学 Q1 PHARMACOLOGY & PHARMACY

Current Opinion in Pharmacology Pub Date : 2023-04-01 DOI:10.1016/j.coph.2023.102348

Manuel Cabeza-Segura , Blanca Garcia-Micò , Marcella La Noce , Giovanni Francesco Nicoletti , Valeria Conti , Amelia Filippelli , Tania Fleitas , Andrés Cervantes , Josefa Castillo , Federica Papaccio

{"title":"How organoids can improve personalized treatment in patients with gastro-esophageal tumors","authors":"Manuel Cabeza-Segura , Blanca Garcia-Micò , Marcella La Noce , Giovanni Francesco Nicoletti , Valeria Conti , Amelia Filippelli , Tania Fleitas , Andrés Cervantes , Josefa Castillo , Federica Papaccio","doi":"10.1016/j.coph.2023.102348","DOIUrl":null,"url":null,"abstract":"<div><p>Gastro-esophageal tumors constitute a big health problem. Treatment options still mainly rely on chemotherapy, and apart from human epidermal growth factor receptor 2<span> positive and microsatellite<span> instable/Epstein–Barr Virus disease, there are no molecularly guided options. Therefore, despite the large number of identified molecular alterations, precision medicine is still far from the clinic. In this context, the recently developed technology of patient-derived organoids (PDOs) could offer the chance to accelerate drug development and biomarker discovery. Indeed, PDOs are 3D primary cultures that were shown to reproduce patient's tumor characteristics. Moreover, several reports indicated that PDOs can replicate patient's response to a given drug; therefore, they are one of the most promising tools for functional precision medicine.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489223000012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 3

Abstract

Gastro-esophageal tumors constitute a big health problem. Treatment options still mainly rely on chemotherapy, and apart from human epidermal growth factor receptor 2 positive and microsatellite instable/Epstein–Barr Virus disease, there are no molecularly guided options. Therefore, despite the large number of identified molecular alterations, precision medicine is still far from the clinic. In this context, the recently developed technology of patient-derived organoids (PDOs) could offer the chance to accelerate drug development and biomarker discovery. Indeed, PDOs are 3D primary cultures that were shown to reproduce patient's tumor characteristics. Moreover, several reports indicated that PDOs can replicate patient's response to a given drug; therefore, they are one of the most promising tools for functional precision medicine.

查看原文本刊更多论文

类器官如何改善胃食管肿瘤患者的个性化治疗

胃食管肿瘤是一个巨大的健康问题。治疗选择仍然主要依赖于化疗，除了人类表皮生长因子受体2阳性和微卫星不稳定/EB病毒病外，没有分子指导的选择。因此，尽管有大量已鉴定的分子改变，但精准医学离临床还很远。在这种情况下，最近开发的患者衍生类器官（PDO）技术可能为加速药物开发和生物标志物发现提供机会。事实上，PDO是3D原代培养物，可以重现患者的肿瘤特征。此外，一些报告表明，PDO可以复制患者对给定药物的反应；因此，它们是功能性精准医学最有前景的工具之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Pharmacology 医学-药学

CiteScore

8.80

自引率

2.50%

发文量

131

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.